Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Warma lists the prerequisites for a registration study: deliver the drug safely, cross the blood-brain barrier to engage target, show biomarker movement, identify a dose, and demonstrate clinical benefit. ProMIS has fast-track designation and plans an end-of-phase-2 FDA meeting. He says these are the boxes that must be checked before starting phase 3.

Related Insights

Instead of waiting 90 days for functional outcomes, Revolicio's Phase 2 trial used MRI scans at 0 and 48 hours to measure brain tissue loss. This provided a direct, early biomarker of the drug's physiological effect, which correlated strongly with later clinical benefits and de-risked the subsequent Phase 3 trial.

To combat high failure rates in CNS, Autobahn designed its Phase 2 study with the statistical power of a Phase 3 trial (+90%). This capital-intensive approach aims to get a definitive answer on drug efficacy early, increasing confidence for a successful Phase 3 replication and avoiding larger, later-stage flameouts.

To raise capital, biotechs need specific clinical data. Raj Devraj specifies the three essential components investors look for: 1) confirmation of good drug exposure in humans, 2) a favorable early safety profile, and 3) biomarker data that provides proof of the drug's biological mechanism. Lacking any of these makes fundraising significantly harder.

In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.

The extensive translational and biomarker work published in Nature from a Phase 1 study of Casdatifan is a model for modern drug development. Understanding the drug's mechanism, pharmacodynamics, and response signatures from day one provides a 'backup plan' and helps avoid costly Phase 3 failures.

Warma says ProMIS chose a 140-patient, 12-month phase 1b instead of a quick 30-patient biomarker study. By checking safety, target engagement, dose, and clinical signal, they hope to move straight into a registration phase 3, saving years and cost. He says the longer, costlier design was deliberate because short biomarker studies left partners unsure.

Neurofilament light chain (NFL) is an undisputed biomarker for neurodegeneration. Consistently negative readings indicate cells are dying less, providing a pure, objective signal that a therapy is working. This data alone should be enough to meet the 'probable benefit' standard for an Accelerated Approval (AA).

Warma says when ProMIS proposed the larger phase 1b, investors were more interested than in a quick-and-dirty study because they saw the path to skipping phase 2. Pharma partners also responded well to the comprehensive design. He notes the tradeoff is a longer public-company news wait and higher cost, but the pros outweighed cons.

Unusually for a Phase 1 safety trial, Gain Therapeutics measured lipid levels in patients' cerebrospinal fluid. They observed a decrease in the target toxic lipids, providing strong, early biological evidence that the drug reaches the brain and works as intended. This de-risks future development by establishing a clear biomarker of effect.

Historically, neuroscience has suffered high clinical failure rates due to heterogeneous patient groups, complex pathologies, and subjective, squishy endpoints. Adopting oncology's playbook of validating objective biomarkers and stratifying patient sub-populations before clinical entry allows drug developers to de-risk trials and verify target engagement early.